The continued increase in prevalence of herpes simplex virus (HSV) infection indicates a need to develop improved chemotherapeutic strategies so as to enhance options for the management of genital herpes. The clinical and psycho-social impact of genital herpes and the need to encourage patients to participate in controlling their disease create several opportunities for improvement.
Summary
The continued increase in prevalence of herpes simplex virus (HSV) infection indicates a need to develop improved chemotherapeutic strategies so as to enhance options for the management of genital herpes. The clinical and psycho-social impact of genital herpes and the need to encourage patients to participate in controlling their disease create several opportunities for improvement.
The higher bioavailability of aciclovir from valaciclovir ensures that plasma aciclovir levels exceed the in vitro IC so for clinical HSV strains with once-or twice-daily dosing regimens. The satisfactory outcome for valaciclovir in pre-clinical mutagenicity and carcinogenicity bioassays, plus aciclovir's highly specific mode of action, form the basis for the proposal that valaciclovir can match the excellent safety profile established for aciclovir.
Controlled clinical trials of valaciclovir for the acute treatment of recurrent genital herpes have demonstrated efficacy in speeding resolution of all signs and symptoms, hastening lesion healing and terminating virus shedding. Further, these results indicate that valaciclovir provides a significant improvement in increasing the numbers of patients in whom lesion development is prevented. These benefits were achieved with twice-daily valaciclovir regimens and without compromise to safety.
Studies evaluating valaciclovir in HSV infections in the immunocompromised and for long-term suppressive therapy in otherwise healthy subjects continue. To date, the valaciclovir HSV clinical development programme indicates that efficacy can be achieved with less frequent dosing without compromising safety.
Keywords: valaciclovir; aciclovir; HSV. The prevalence of genital herpes simplex virus (HSV) infection has increased markedly over the past 20 years in both developed and third-worldcountries (Johnson et ei., 1989; Corey, 1990; Nahmias et el., 1990; Barton, 1995; Johnson, R., et el., Abstract 113, International Society for STD Research, Helsinki, 29-31 August 1993) . Between 1976 and 1980, seroprevalence for HSV type 2 (HSV-2) antibody was 16.4%, whereas by 1991 it had increased to almost 22%. In western industrialized nations, genital HSV infection is the most common causal agent isolated from anogenital ulcers in patients attending sexually transmitted disease clinics . Clinical signs and symptoms of genital HSV infection may be absent or go unrecognized in up to 70% of HSV-2 seropositive subjects (Koutsky et el., 1992; Catotti et el., 1993) .
Most genital herpes is caused by HSV-2, although the occurrence of genital infection caused by HSV type 1 (HSV-1) appears to be increasing (Kinghorn, 1993) . Following primary infection and the establishment of latency, recurrent episodes of genital herpes occur, with those caused by HSV-2 tending to appear sooner and more frequently after the initial episode than those due to HSV-1 (Reeves et el., 1981; Lafferty et el., 1987) . The clinical manifestations of genital herpes, whether caused by HSV-1 or HSV-2, are qualitatively similar, but with the signs and symptoms of primary disease being markedly more severe and prolonged than those of recurrent episodes (Fig. 1) .
The psycho-sexual morbidity associated with genital herpes significantly impairs the quality of life of patients (Manne and Sandler, 1984; Goldmeier et el., 1988) . This is due not only to the clinical characteristics and frequency of recurrent attacks, but also to the socially stigmatizing na!ure of sexually transmitted diseases, the potential for transmission of herpes to uninfected partners during periods of virus shedding, and because genital ulcer disease is believed to be a risk factor for the acquisition of human immunodeficiency virus infection (Rooney et el., 1986; Stamm et el., 1988; Bryson et ei., 1993) .
Aciclovir -the current standard
Aciclovir is currently the most widely prescribed agent in the management of genital herpes (Corey, 1990; de Fig. 1 . Median duration of key signs and symptoms of initial and recurrent genital herpes simplex infection. (Data from Nilsen et et., 1982; Kinghorn et el., 1983; Salo et 131., 1983; Reichman et al., 1984.) Ruiter and Thin, 1994). Its efficacy and safety, in a range of formulations, have been extensively reviewed (O'Brien and Campoli-Richards, 1989) .
In placebo-controlled clinical trials, oral and intravenous aciclovir provide better efficacy than topical formulations. Acute treatment with the systemic formulations not only markedly shortened the duration of virus shedding and lesion healing (which were the objective clinical endpoints), but also conferred measurable benefit on the severity and duration of systemic symptoms and the more subjective pain-related aspects (de Ruiter and Thin, 1994) . With prolonged use over periods of months or years, oral aciclovir has also been shown to reduce markedly the frequency of genital herpes recurrences and to enhance the quality of life of patients (Douglas et al., 1984; Mindel et al., 1984; Carney et et., 1993) . Recently,in a placebo-controlled crossover study, the use of oral aciclovir was demonstrated to suppress subclinical HSV shedding as well as genital herpes recurrences, and, in theory, could reduce transmission (Wald, A., et al., Abstract, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 4-7 October 1994). This effect was particularly evident in the 6 months following initial HSV-2 infection.
Sensitivity monitoring of clinical HSV isolates has shown that the use of aciclovir for the management of genital herpes in immunocompetent patients is not associated with the widespread emergence of HSV-resistant strains (Collins and Ellis, 1993) . Continued surveillance for resistance continues to be necessary as new antiherpes drugs are introduced into clinical practice.
The exceptional safety record of oral aciclovir has been established from over 10 years' clinical practice and 32 million patient exposures (Tilson et sl., 1993) . The extensive and continuing safety monitoring programme has
Improvement opportunities
The oral bioavailability and plasma elimination half-life of aciclovir in man are limited (de Miranda and Blum, 1983 ). An oral drug or formulation that provides higher and/or more prolonged plasma aciclovir exposure would be advantageous because appropriate blood levels could be achieved with more convenient and less frequent dosing regimens. The current recommendation is five times daily for the acute treatment of primary and recurrent genital HSV infection, or twice or four times daily for suppression. It is well recognized in medicine that, for prophylaxis, once-daily regimens are optimal and ensure better compliance (Eisen et al., 1990) .
Education about the many facets of genital herpes must continue so that patients are encouraged to help control their disease and hence their lives (Mindel, 1993) . In patients with recognizable prodromal symptoms preceding a recurrent genital herpes episode, there is an excellent opportunity for early administration of effective demonstrated consistently good tolerability with a sustained absence of major medical problems.
The safety profile of aciclovir is unique amongst nucleoside analogues, and is thought to "result at least in part from its highly selective mode of action. Other nucleoside analogues in clinical use, specifically ganciclovir and tarnciclovir (the oral prodrug of penciclovir), are structurally similar to aciclovir and share some similarities with its mode of action. However, they differ in that they are not obligate chain terminators of herpesvirus replication. Because it is associated with bone-marrow toxicity, the use of ganciclovir is restricted to immunocompromised patients who are at risk of cytomegalovirus infection or reactivation (Foulds and Heel, 1990) . The marked difference between the clinical safety profiles of aciclovir and ganciclovir, despite only minor alteration in chemical structure, serves to illustrate the absence of a class effect being applicable, in terms of safety, to nucleoside analogues as antiherpes agents. Hence, formal clinical evaluation and subsequent experience in clinical practice should be regarded as essential before drawing conclusions regarding the safety of any new nucleoside analogue.
The proven efficacy and established safety of aciclovir in the management of genital herpes are the foundation on which improvements in chemotherapy can be based. Herpes simplex virus type 1 and HSV-2 are the human herpesviruses that are most sensitive to inhibition by aciclovir (Collins, 1983; Wagstaff et al., 1994) , and plasma aciclovir concentrations within the range of in vitro IC so values can be achieved with the oral formulation; however, the multi-dimensional profile of genital herpes provides several opportunities for improvements in its management. © 1995Blackwell Science Ltd, Antiviral Chemistry and Chemotherapy, 6, Supplement 1, 39-44 antiviral agents that should inhibit viral replication within sensory nerves and thus prevent subsequent damage to skin and mucous membranes. Retrospective evidence and open observations supporting this concept of prevention of lesion development with prodromal aciclovir treatment have already been described (Ruhnek-Forsbeck et el., 1985; Goldberg et el., 1988; Whatley and Thin, 1991) .
Virus shedding can occur from ulcerating lesions and may also occur subclinically (Corey, 1990; Mertz, 1990) , so that prevention of lesion development should shorten the period of shedding and, in turn, reduce the risk of transmission. Patients requiring sustained treatment for genital HSV suppression will need assurance that new drug regimens and therapies are efficacious in preventing both symptoms and subclinical virus shedding.
To date, no antiviral agent or other strategy has been advocated for prevention of herpesvirus latency in man. Although results from animal experiments have shown that latency in nerve root ganglia can be prevented if aciclovir is administered within 3 h of exposure to HSV (Klein et sl., 1979) , in clinical practice a comparable situation is unlikely because, in reality, a delay of several days after exposure and subsequent development of symptoms generally occurs before medical attention is sought (de Ruiter and Thin, 1994) . Ongoing studies evaluating HSV vaccines may eventually provide a means of reducing the risk of transmission. A role for antivirals in influencing transmission remains to be determined.
A range of options continues to be necessary for the effective clinical management of patients with genital herpes (de Ruiter and Thin, 1994) . For some, short-term or episodic chemotherapy producing rapid resolution of the symptoms may be appropriate, while for others longer-term suppressive therapy may be preferred. The clinical development programme for valaciclovir addresses the broad range of key features that characterize primary and recurrent genital HSV infection.
The potential of valaciclovir
Valaciclovir, the L-valine ester of aciclovir, was selected for clinical development as therapy for a range of herpesvirus indications because it possesses many of the characteristics demanded of the next generation of antiherpes agents and of formulations providing greater exposure to known therapeutic entities (Stella et ei., 1985; Whitley and Gnann, 1993) . Of prime importance are the more favourable aciclovir pharmacokinetic profile from valaciclovir and the pre-clinical safety profile which is comparable to that of the established standard, aciclovir (Weller et el., 1993; Nusinoff-Lehrman et st., 1993) . Further, and with relevance to its potential for long-term use as suppressive therapy for recurrent genital herpes, valaciclovir was negative in standard rodent carcinogene-Valacic/ovir in genital herpes 41 sis bioassays at maximum tolerated doses (G. Szczech and P. de Miranda, Burroughs Wellcome Co., USA, personal communication).
After oral administration, valaciclovir is readily absorbed and then undergoes almost complete (99%) hydrolysisto aciclovirand the essentialamino acid, L-valine. Valaciclovir itself has negligible pharmacological activity and, with the exception of aciclovir, all products of its metabolism and disposition are inert, non-toxic and wellcharacterized (de Miranda et al., 1981; Nusinoff-Lehrman et al., 1993; Weller et el., 1993) .Thus, it is logical to expect that the safety profiles of valaciclovir and aciclovir will be similar in clinical practice.
The enhanced aciclovir bioavailability provided by oral valaciclovir is three-to five-fold greater than that which can be achieved with oral aciclovir (Weller et al., 1993) . The clinical development programme for valaciclovir was designed to determine whether the higher plasma aclclovir exposure following oral valaciclovir would retain or enhance efficacy with less frequent oral dosing regimens, without compromise to the safety profile established for aciclovir. Superior clinical benefit in hastening resolution of the pain of herpes zoster has been demonstrated for valaciclovir (1000 mg tds) over aciclovir (800 mg five times daily) in a double-blind, randomized, controlled trial in patients aged 50 years or older (Beutner et al., 1995) . The safety profiles of valaciclovir and aciclovir were com" parable.
Antiviral activity
The affinity of aciclovir triphosphate for HSV-1 DNA polymerase is similar to that for HSV-2, at 0.07 flM and 0.08 flM, respectively (Ertl et al., 1995) . This is reflected in the in vitro inhibitory activity of aciclovir, as estimated by plaque reduction assays of clinical isolates of HSV-1 and HSV-2, for which IC so values of 1.8 flM and 1.7 flM, respectively, are recorded (Littler, 1994) . In contrast, penciclovir triphosphate has a lower affinity for both HSV-1 and HSV-2 DNA polymerases (K; of 11 flM and 6 flM, respectively) and is less effective in inhibiting HSV-2 replication in vitro compared with HSV-1 (IC so of 12.8 flM compared with 3.9 flM) (Earnshaw et el., 1992; Littler, 1994) . These intracellular kinetic findings may be of relevance to the clinical situation because, in the absence of routine HSV type-specific serology testing, the mode of drug action, dosage regimen and efficacy must give good inhibition of both HSV-1 and HSV-2 genital herpes.
Clinical trials -efficacy endpoints, data analysis and safety
The clinical efficacy of aciclovir in genital and non-genital HSV infections has been demonstrated in numerous con- trolled clinical trials (Whitley and Gnann, 1992) . This is the basis of the rationale for valaciclovir being effective in the management of genital herpes.
Placebo-controlled trials of aciclovir in the acute treatment of genital herpes traditionally determined the time-toevent for lesion stages and healing: the end of virus shedding, and loss of pain or other discomfort. In studies evaluating valaciclovir for the acute treatment of both primary and recurrent genital herpes, the principal efficacy endpoints also included the duration of the whole episode, from dosing to complete re-epithelialization of skin or mucous membrane, and resolution of all pain and discomfort. In primary or first-episode disease only, the duration and severity of systemic symptoms were also included in the assessment of efficacy. For recurrent HSV episodes valaciclovir trials have determined prospectively the number of patients in whom lesions are prevented, i.e. those whose lesions did not progress beyond the papule stage.
Estimates of efficacy in the earlier aciclovir trials were usually presented in terms of differences between mean or median values for each event (Nilsen et al., 1982; Kinghorn et el., 1983; Salo et al., 1983; Reichman et al., 1984) . In valaciclovir clinical trials, Kaplan-Meier 'survival' analysis of the distribution of events (endpoints), with the application of the principle of intent-to-treat analysis, has been adopted; this generates a clinical picture describing the resolution of symptoms or signs against time (Fig. 2) . The comparative efficacy of two treatments for each endpoint can then be quantified by proportional hazard regression and deriving a hazard ratio, thus making maximum use of all available data. A hazard ratio (95% confidence intervals [Cis]) of 2.0 (1.8, 2.2) means, for example, that the event rate in one treatment occurs on average twice as rapidly as with the other treatment. Since the 95% CIs are greater than 1.0 in this example, the treatments may be considered significantly different from each other. Valaciclovir is undergoing evaluation for the acute treatment of genital herpes in twice-daily dose regimens of 500 mg and 1000 mg (Fig. 3) . The resultant systemic aciclovir exposures from oral valaciclovir at steady state are approximately 1.5 and 3 times that achieved with oral aciclovir in the approved regimen of 200 mg five times daily.
Preliminary results of the first of a series of controlled, randomized trials of valaciclovir in the treatment of recurrent genital herpes indicated that valaciclovir (1000 mg or 500 mg twice daily) and aciclovir (200 mg five times daily) significantly accelerated the resolution of all clinical signs and symptoms, and hastened lesion healing compared with placebo. Treatment with valaciclovir was consistently associated with increased numbers of patients in whom lesion development was prevented. No difference in the occurrence of adverse events was evident between valaciclovir, aciclovir and placebo treatment groups. (Smiley, L.M., et al., Abstract, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 17-20 October 1993; Barton, S., et al., Abstract, European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 25-30 March 1995) . These findings indicate that the advantages of aciclovir in the treatment of recurrent genital herpes are retained with the more convenient twice-daily valaciclovir dosage regimen.
Given the wide acceptance of the efficacy and safety of aciclovir for long-term suppressive therapy in genital herpes (Corey, 1990; de Ruiter and Thin, 1994) , it is not considered acceptable to maintain patients in clinical trials on placebo or suboptimal dose regimens for long periods. The time-to-event approach thus continues to be used in the design and data analysis of suppression trials of ----Valaciclovir 500 mg bd --------------Valaciclovir 1000 mg bd ---Aciclovir 200 mg x 5 daily ::::::::::::::::: IC so range for clinical HSV strains 0 valaciclovir, with the preference being to determine the time to the first recurrence after starting therapy. As with any new therapy for long-term use in clinical practice, the long-term safety of valaciclovir for genital HSV suppression is being carefully monitored. Oral aciclovir has been administered to otherwise healthy subjects with recurrent genital herpes for periods of up to 10 years. Interim reports to 7 years continue to indicate highly acceptable clinical tolerability and no evidence of significant side-effects or cumulative toxicity (Goldberg et et., 1993; D. Baker, personal communication, 3rd Congress of the European Academy of Dermatology and Venereology, Copenhagen, 26-30 September 1993).
Conclusion -a bright future
The increasing prevalence of genital herpes impacts in several diverse ways, including sociological, epidemiological, economic and clinical. The future pattern of prevalence may be influenced favourably by more education and with advances in vaccine design; however, further improvements in chemotherapy to SUPR0rt evolving management strategies will continue to playa major role in the short-to medium-term at least.
The clinical impact of the improved aciclovir pharmacokinetic profile from valaciclovir has already been demonstrated in the treatment of zoster, with valaciclovir providing faster pain resolution (Beutner et al., 1995) . In genital herpes, valaciclovir treatment ensures rapid resolution of all signs and symptoms, hastening lesion healing and increasing numbers of patients in whom lesion development is prevented. These advances are achieved with simpler thrice-daily (zoster) and twice-daily (genital herpes) oral regimens compared with the five-times daily dose frequency recommended for oral aciclovir, and without compromise to the excellent safety profile which characterizes aciclovir.
Ongoing and future trials of valaciclovir in genital herpes are building on the foundation of aciclovir and the encouraging preliminary results for valaciclovir. Valaciclovir looks set to provide a means by which short-and longterm chemotherapy for genital herpes will be reliable in terms of efficacy and safety, and discreet through lessfrequent dose regimens.
